Drug-drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review

  1. Beatriz Oda Plasencia-García
  2. Gonzalo Rodríguez-Menéndez
  3. María Isabel Rico-Rangel
  4. Ana Rubio-García
  5. Jaime Torelló-Iserte
  6. Benedicto Crespo-Facorro

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1007/s00213-020-05716-4
  2. ScreenIT

    SciScore for 10.1101/2020.06.04.20122416: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board Statementnot detected.
    RandomizationInclusion and exclusion criteria: The characteristics for a study to be eligible were (1) Publication reporting clinically significant drug-drug interactions (between antipsychotics and COVID-10 treatment in adult patients (whatever the disease prescribed for), (2) Type of publication: randomized controlled trial, other controlled study, observational study, case report and case series.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.

    Table 2: Resources

    Software and Algorithms
    SentencesResources
    We researched the following databases: MEDLINE, EMBASE, and Web of Science.
    MEDLINE
    suggested: (MEDLINE, RRID:SCR_002185)
    EMBASE
    suggested: (EMBASE, RRID:SCR_001650)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    Thus, patients on concomitant olanzapine and ritonavir may require higher doses (up to 50% more) of olanzapine to achieve similar plasma concentrations54,55 Strengths & Limitations: The use of drug interaction databases can be a useful clinical tool, but the lack of agreement between them limits their use56–60. Our study reviewed DDIs in 3 databases which fulfill quality criteria39,40, and a systematic review of the literature was also dome in search of possible clinical outcomes of these DDIs. The main treatments used internationally for the treatment of COVID-19 were included, as well as most antipsychotics. As limitations of our study, it should be noted that no studies were found beyond clinical cases which examined clinical results of the interaction between the drugs studied, so this information could not be presented.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.06.04.20122416v1 on medRxiv